Systemic therapy in metastatic renal cell carcinoma.

about

Systemic therapy in metastatic renal cell carcinoma.

Item

http://www.wikidata.org/entity/Q35851695

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Systemic therapy in metastatic renal cell carcinoma.

@ast

Systemic therapy in metastatic renal cell carcinoma.

@en

type

Item

label

Systemic therapy in metastatic renal cell carcinoma.

@ast

Systemic therapy in metastatic renal cell carcinoma.

@en

prefLabel

Systemic therapy in metastatic renal cell carcinoma.

@ast

Systemic therapy in metastatic renal cell carcinoma.

@en

P1476

Systemic therapy in metastatic renal cell carcinoma.

@en

P2093

S O Pyrhönen

http://www.w3.org/2001/XMLSchema#string

P2860

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer.

Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.

Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma.

Phase II trial of thalidomide for patients with advanced renal cell carcinoma.

Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma.

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma.

Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

P304

156-161

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/145749690409300212

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15285569

http://www.w3.org/2001/XMLSchema#string